US-based therapeutic development company, AiVita Biomedical has secured the California Institute for Regenerative Medicine (CIRM) grant to develop stem cell-derived 3D-transplantable retinas to treat vision loss.

The development project is being conducted in collaboration with University of California, and Irvine (UCI) Sue & Bill Gross Stem Cell Research Centre assistant professor Magdalene Seiler.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Aivita will be responsible for manufacturing the 3D-retinal organoids and will use its GMP manufacturing, quality and regulatory systems to render the process clinically and commercially compliant.

"The device is intended to address macular degeneration and retinitis pigmentosa by using human stem cells differentiated into sheets of retinal tissue to restore visual responses."

UCI will have the responsibility of evaluating the safety and efficacy of the device in addressing retinal degeneration.

AiVita CEO Dr Hans Keirstead said: "We are proud to have achieved such a major milestone, the restoration of visual acuity in models of advanced retinal degeneration, using a human stem cell population that is ethically procured, renewable and cost effective.

See Also:

"We are very thankful to CIRM for supporting the further development of this important programme."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device, to be manufactured under the project, is intended to address macular degeneration and retinitis pigmentosa by using human stem cells differentiated into sheets of retinal tissue to restore visual responses.

It is reported that the existing approaches can only target limited disease stages through methods such as transient trophic support for degenerating retinal cells within the patient.

According to AiVita team, the new project will enable them to treat a greater number of retinal disorders at various stages compared to current approaches.